Biohaven Pharmaceuticals, Inc: Developing a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. Internal development and research with intellectual property licensed from companies and institutions including BMS, AstraZeneca, Yale University, Catalent, ALS Biopharma and Massachusetts General Hospital.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM +
Therapeutic Modalities
Small Molecule
Website:
Address:
215 Church Street
New Haven, CT 06510
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.